654 related articles for article (PubMed ID: 12517253)
1. Cannabinoids for gastrointestinal diseases: potential therapeutic applications.
Di Carlo G; Izzo AA
Expert Opin Investig Drugs; 2003 Jan; 12(1):39-49. PubMed ID: 12517253
[TBL] [Abstract][Full Text] [Related]
2. Cannabinoids and the digestive tract.
Izzo AA; Coutts AA
Handb Exp Pharmacol; 2005; (168):573-98. PubMed ID: 16596788
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoids and the gut: new developments and emerging concepts.
Izzo AA; Sharkey KA
Pharmacol Ther; 2010 Apr; 126(1):21-38. PubMed ID: 20117132
[TBL] [Abstract][Full Text] [Related]
4. The gastrointestinal pharmacology of cannabinoids.
Izzo AA; Mascolo N; Capasso F
Curr Opin Pharmacol; 2001 Dec; 1(6):597-603. PubMed ID: 11757815
[TBL] [Abstract][Full Text] [Related]
5. Endocannabinoids and the gut.
Pinto L; Capasso R; Di Carlo G; Izzo AA
Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):333-41. PubMed ID: 12052047
[TBL] [Abstract][Full Text] [Related]
6. Endocannabinoids and the gastrointestinal tract.
Massa F; Monory K
J Endocrinol Invest; 2006; 29(3 Suppl):47-57. PubMed ID: 16751708
[TBL] [Abstract][Full Text] [Related]
7. The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonoylglycerol) are blocked by delta(9)-tetrahydrocannabinol and other cannnabinoids.
Darmani NA
J Pharmacol Exp Ther; 2002 Jan; 300(1):34-42. PubMed ID: 11752094
[TBL] [Abstract][Full Text] [Related]
8. Role of cannabis in digestive disorders.
Goyal H; Singla U; Gupta U; May E
Eur J Gastroenterol Hepatol; 2017 Feb; 29(2):135-143. PubMed ID: 27792038
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development.
Pertwee RG
Expert Opin Investig Drugs; 2000 Jul; 9(7):1553-71. PubMed ID: 11060760
[TBL] [Abstract][Full Text] [Related]
10. Cannabis and cannabinoids: pharmacology and rationale for clinical use.
Pertwee RG
Forsch Komplementarmed; 1999 Oct; 6 Suppl 3():12-5. PubMed ID: 10575283
[TBL] [Abstract][Full Text] [Related]
11. Cannabinoid receptors and their ligands.
Pertwee RG; Ross RA
Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):101-21. PubMed ID: 12052030
[TBL] [Abstract][Full Text] [Related]
12. Endocannabinoid overactivity and intestinal inflammation.
Di Marzo V; Izzo AA
Gut; 2006 Oct; 55(10):1373-6. PubMed ID: 16966693
[TBL] [Abstract][Full Text] [Related]
13. The gastrointestinal tract - a central organ of cannabinoid signaling in health and disease.
Hasenoehrl C; Taschler U; Storr M; Schicho R
Neurogastroenterol Motil; 2016 Dec; 28(12):1765-1780. PubMed ID: 27561826
[TBL] [Abstract][Full Text] [Related]
14. Cannabinoids.
Grotenhermen F
Curr Drug Targets CNS Neurol Disord; 2005 Oct; 4(5):507-30. PubMed ID: 16266285
[TBL] [Abstract][Full Text] [Related]
15. Endocannabinoids and the Digestive Tract and Bladder in Health and Disease.
Izzo AA; Muccioli GG; Ruggieri MR; Schicho R
Handb Exp Pharmacol; 2015; 231():423-47. PubMed ID: 26408170
[TBL] [Abstract][Full Text] [Related]
16. Cannabinoid receptors and pain.
Pertwee RG
Prog Neurobiol; 2001 Apr; 63(5):569-611. PubMed ID: 11164622
[TBL] [Abstract][Full Text] [Related]
17. Cannabinoid pharmacology and therapy in gut disorders.
Uranga JA; Vera G; Abalo R
Biochem Pharmacol; 2018 Nov; 157():134-147. PubMed ID: 30076849
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of cannabinoids in CNS disease.
Croxford JL
CNS Drugs; 2003; 17(3):179-202. PubMed ID: 12617697
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoids and intestinal motility: welcome to CB2 receptors.
Izzo AA
Br J Pharmacol; 2004 Aug; 142(8):1201-2. PubMed ID: 15277313
[TBL] [Abstract][Full Text] [Related]
20. Endocannabinoid structure-activity relationships for interaction at the cannabinoid receptors.
Reggio PH
Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):143-60. PubMed ID: 12052032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
